Gene testing of new brain tumors in young people
Original title: Targeted Pediatric High-Grade Glioma Therapy
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
No phase was given for this study, and it is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study looks at the genes in a child's or young adult's newly found high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary.
Who this trial is for. This study is for children, teens, and young adults just diagnosed with a high-grade glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are given a grade from 1 to 4 describing how the tumor is expected to behave. See the glossary. It tests the genes in the tumor to see if the person may fit a later treatment trial.
Where it stands. This study has not reported results. It is looking at what gene changes show up in each tumor. Those results are then used to see who may fit a later treatment trial. The full picture is not in yet.
What this means, and what it doesn't
What it could mean: Gene testing can show more about what is driving a tumor. That may open the door to a later trial that targets those gene changes. Someone who fits this picture could ask their care team about it.
What it doesn't mean: This does not mean a treatment has been proven. A trial is a test, not care your doctor can give you. Joining a trial is not a promise that it will help. This is not a cure, and gene testing here does not mean a matching treatment will be found.
Source: ClinicalTrials.gov, September 8, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.